Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Digestive System Diseases

Rare Diseases

Urinary Bladder Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Acute Graft Versus Host Disease

Enadenotucirev

This is a multicentre, open-label, Phase I/II study of enadenotucirev in patients with either solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists (Phase I dose escalation stage Single cycle), mCRC not responding to standard therapy (Phase I dose escalation Repeat cycle cohort expansion stage ), mCRC not responding to standard therapy or advanced or metastatic bladder cancer not candidate for chemotherapy (Phase Ib) or mCRC in stable disease or partial response after 3-4 months of first line standard of care chemotherapy (Phase II).

Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients

A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer

- Maximum tolerated dose (MTD) / maximum feasible dose (MFD) of enadenotucirev when administered by sub-acute fractionated IV injection (phase I Dose Escalation) and recommended dose for phase II.

Open label assessment of 2 repeat cycle schedules, with expansion cohort at the MTD or MFD with best repeat cycle schedule in advanced/metastatic UBC patients.

Akamis Bio

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients	NCT02028442	Solid Tumours o... Metastatic Colo... Metastatic Blad...	Enadenotucirev	18 Years -	Akamis Bio
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients	NCT02028442	Solid Tumours o... Metastatic Colo... Metastatic Blad...	Enadenotucirev	18 Years -	Akamis Bio

Spots Global Cancer Trial Database for solid tumours of epithelial origin